Beam Therapeutics Inc. (NASDAQ: BEAM) announced it will present updated biomarker data from its BEACON Phase 1/2 clinical trial at ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE